Search

Your search keyword '"Kang, Amy"' showing total 181 results
Start Over Author "Kang, Amy"
181 results on '"Kang, Amy"'

1. EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study

Author

Foote, Celine, Hockham, Carinna, Sukkar, Louisa, Campain, Anna, Kang, Amy, Young, Tamara, Cass, Alan, Chow, Clara K, Comino, Elizabeth, Gallagher, Martin, Jan, Stephen, Knight, John, Liu, Bette, McNamara, Martin, Peiris, David, Pollock, Carol, Sullivan, David, Wong, Germaine, Zoungas, Sophia, Rogers, Kris, Jun, Min, and Jardine, Meg

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundChronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations. ObjectiveThis study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes. MethodsIn the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes. ResultsThe study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development. ConclusionsThe EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals. International Registered Report Identifier (IRRID)RR1-10.2196/15646

Published
2020
Full Text
View/download PDF

2. Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales

Author

Kang, Amy Y, Elkomos, Mary, Pham, Danny, Guerrero, Michelle, Kupferwasser, Deborah, and Miller, Loren G

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Minority Health, Health Disparities, Infection
Abstract

ObjectiveTo investigate whether empiric carbapenem therapy, compared to empiric non-carbapenem therapy, was associated with improved clinical outcomes among hospitalized, non-intensive care unit (ICU) patients with extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections.MethodsWe performed a retrospective cohort study of adult, non-ICU patients admitted with ESBL-producing Enterobacterales infections. Primary outcome was time to clinical stability from the first empiric antibiotic dose. Secondary outcomes were early clinical response and 30-day all-cause hospital readmission. We used multivariate regression methods to examine time to clinical stability.ResultsOf the 142 patients, 59 (42%) received empiric carbapenems and 83 (58%) received empiric non-carbapenems, most commonly ceftriaxone (49/83, 59%). Median age was 59 years. The most common infection source was urinary (71%). The carbapenem group had a higher proportion of patients who received antibiotics within 6 months of admission (55% vs 28%, P < .01) and history of ESBL (57% vs 17%, P < .01). There were no significant differences in hours until clinical stability between the carbapenem and non-carbapenem groups (22 (IQR: 0, 85) vs 19 (IQR: 0, 69), P = .54). Early clinical response (88% vs 90%, P = .79) and 30-day all-cause hospital readmission (17% vs 8%, P = .13) were similar between groups.ConclusionAmong hospitalized non-ICU patients with ESBL-producing Enterobacterales infection, we found no difference in time to clinical stability after the first empiric antibiotic dose between those receiving carbapenems and those who did not. Our data suggest that empiric carbapenem use may not be an important driver of clinical response in patients with less severe ESBL-producing Enterobacterales infection.

Published
2024

4. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

Author

Perkovic, Vlado, Mahaffey, Kenneth W., Agarwal, Rajiv, Bakris, George, Brenner, Barry M., Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Greene, Tom, Jardine, Meg J., Heerspink, Hiddo J.L., Levin, Adeera, Meininger, Gary, Neal, Bruce, Pollock, Carol, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Jardine, Meg, Li, Nicole, Kolesnyk, Inna, Aizenberg, Diego, Pecoits-Filho, Roberto, Cherney, David, Obrador, Gregorio, Chertow, Glenn, Chang, Tara, Hawley, Carmel, Ji, Linong, Wada, Takashi, Jha, Vivekanand, Lim, Soo Kun, Lim-Abrahan, Mary Anne, Santos, Florence, Chae, Dong-Wan, Hwang, Shang-Jyh, Vazelov, Evgueniy, Rychlík, Ivan, Hadjadj, Samy, Krane, Vera, Rosivall, László, De Nicola, Luca, Dreval, Alexander, Nowicki, Michał, Schiller, Adalbert, Distiller, Larry, Górriz, Jose L., Kolesnyk, Mykola, David, Wheeler, C., Guerrero, Rodolfo Andres Ahuad, Albisu, Juan Pablo, Alvarisqueta, Andres, Bartolacci, Ines, Berli, Mario Alberto, Bordonava, Anselmo, Calella, Pedro, Cantero, Maria Cecilia, Cartasegna, Luis Rodolfo, Cercos, Esteban, Coloma, Gabriela Cecilia, Colombo, Hugo, Commendatore, Victor, Cuadrado, Jesus, Cuneo, Carlos Alberto, Cusumano, Ana Maria, Douthat, Walter Guillermo, Dran, Ricardo Dario, Farias, Eduardo, Fernandez, Maria Florencia, Finkelstein, Hernan, Fragale, Guillermo, Fretes, Jose Osvaldo, Garcia, Nestor Horacio, Gastaldi, Anibal, Gelersztein, Elizabeth, Glenny, Jorge Archibaldo, Gonzalez, Joaquin Pablo, Colaso, Patricia del Carmen Gonzalez, Goycoa, Claudia, Greloni, Gustavo Cristian, Guinsburg, Adrian, Hermida, Sonia, Juncos, Luis Isaias, Klyver, Maria Isabel, Kraft, Florencia, Krynski, Fernando, Lanchiotti, Paulina Virginia, Leon de la Fuente, Ricardo Alfonso, Marchetta, Nora, Mele, Pablo, Nicolai, Silvia, Novoa, Pablo Antonio, Orio, Silvia Ines, Otreras, Fabian, Oviedo, Alejandra, Raffaele, Pablo, Resk, Jorge Hector, Rista, Lucas, Papini, Nelson Rodriguez, Sala, Jorgelina, Santos, Juan Carlos, Schiavi, Lilia Beatriz, Sessa, Horacio, Casabella, Tomas Smith, Ulla, Maria Rosa, Valdez, Maria, Vallejos, Augusto, Villarino, Adriana, Visco, Virginia Esther, Wassermann, Alfredo, Zaidman, Cesar Javier, Cheung, Ngai Wah, Droste, Carolyn, Fraser, Ian, Johnson, David, Mah, Peak Mann, Nicholls, Kathy, Packham, David, Proietto, Joseph, Roberts, Anthony, Roger, Simon, Tsang, Venessa, Raduan, Roberto Abrão, Costa, Fernando Augusto Alves da, Amodeo, Celso, Turatti, Luiz Alberto Andreotti, Bregman, Rachel, Sanches, Fernanda Cristina Camelo, Canani, Luis Henrique, Chacra, Antônio Roberto, Borges, João Lindolfo Cunha, Vêncio, Sérgio Alberto Cunha, Franco, Roberto Jorge da Silva, d’Avila, Domingos, Portes, Evandro de Souza, de Souza, Pedro, Deboni, Luciane Mônica, Fraige Filho, Fadlo, Neto, Bruno Geloneze, Gomes, Marcus, Kohara, Suely Keiko, Keitel, Elizete, Saraiva, Jose Francisco Kerr, Lisboa, Hugo Roberto Kurtz, Contieri, Fabiana Loss de Carvalho, Milagres, Rosângela, Junior, Renan Montenegro, de Brito, Claudia Moreira, Hissa, Miguel Nasser, Sabbag, Ângela Regina Nazario, Noronha, Irene, Panarotto, Daniel, Filho, Roberto Pecoits, Pereira, Márcio Antônio, Saporito, Wladmir, Scotton, Antonio Scafuto, Schuch, Tiago, de Almeida, Roberto Simões, Ramos, Cássio Slompo, Felício, João Soares, Thomé, Fernando, Hachmann, Jean Carlo Tibes, Yamada, Sérgio, Hayashida, Cesar Yoiti, Petry, Tarissa Beatrice Zanata, Zanella, Maria Teresa, Andreeva, Viktoria, Angelova, Angelina, Dimitrov, Stefan, Genadieva, Veselka, Genova-Hristova, Gabriela, Hristozov, Kiril, Kamenov, Zdravko, Koundurdjiev, Atanas, Lozanov, Lachezar, Margaritov, Viktor, Nonchev, Boyan, Rangelov, Rangel, Shinkov, Alexander, Temelkova, Margarita, Velichkova, Ekaterina, Yakov, Andrian, Aggarwal, Naresh, Aronson, Ronnie, Bajaj, Harpreet, Chouinard, Guy, Conway, James, Cournoyer, Serge, DaRoza, Gerald, De Serres, Sacha, Dubé, François, Goldenberg, Ronald, Gupta, Anil, Gupta, Milan, Henein, Sam, Khandwala, Hasnain, Leiter, Lawrence, Madore, François, McMahon, Alan, Muirhead, Norman, Pichette, Vincent, Rabasa-Lhoret, Remi, Steele, Andrew, Tangri, Navdeep, Torshizi, Ali, Woo, Vincent, Zalunardo, Nadia, Montenegro, María Alicia Fernández, Gonzalo Godoy Jorquera, Juan, Fariña, Marcelo Medina, Gajardo, Victor Saavedra, Vejar, Margarita, Chen, Nan, Chen, Qinkai, Gan, Shenglian, Kong, Yaozhong, Li, Detian, Li, Wenge, Li, Xuemei, Lin, Hongli, Liu, Jian, Lu, Weiping, Mao, Hong, Ren, Yan, Song, Weihong, Sun, Jiao, Sun, Lin, Tu, Ping, Wang, Guixia, Yang, Jinkui, Yin, Aiping, Yu, Xueqing, Zhao, Minghui, Zheng, Hongguang, Mendoza, Jose Luis Accini, Arcos, Edgar, Avendano, Jorge, Diaz Ruiz, Jorge Ernesto Andres, Ortiz, Luis Hernando Garcia, Gonzalez, Alexander, Triana, Eric Hernandez, Higuera, Juan Diego, Malaver, Natalia, de Salazar, Dora Inés Molina, Rosero, Ricardo, Alexandra Terront Lozano, Monica, Cometa, Luis Valderrama, Valenzuela, Alex, Vargas Alonso, Ruben Dario, Villegas, Ivan, Yupanqui, Hernan, Bartaskova, Dagmar, Barton, Petr, Belobradkova, Jana, Dohnalova, Lenka, Drasnar, Tomas, Ferkl, Richard, Halciakova, Katarina, Klokocnikova, Vera, Kovar, Richard, Lastuvka, Jiri, Lukac, Martin, Pesickova, Satu, Peterka, Karel, Pumprla, Jiri, Rychlik, Ivan, Saudek, Frantisek, Tesar, Vladimir, Valis, Martin, Weiner, Pavel, Zemek, Stanislav, Alamartine, Eric, Borot, Sophie, Cariou, Bertrand, Dussol, Bertrand, Fauvel, Jean-Pierre, Gourdy, Pierre, Klein, Alexandre, Le Meur, Yannick, Penfornis, Alfred, Roussel, Ronan, Saulnier, Pierre-Jean, Thervet, Eric, Zaoui, Philippe, Burst, Volker, Faghih, Markus, Faulmann, Grit, Haller, Hermann, Jerwan-Keim, Reinhold, Maxeiner, Stephan, Paschen, Björn, Plassmann, Georg, Rose, Ludger, Gonzalez Orellana, Ronaldo Arturo, Haase, Franklin Paul, Moreira Diaz, Juan Pablo, Ramirez Roca, Luis Alberto, Sánchez Arenales, Jose Antonio, Sanchez Polo, José Vicente, Juarez, Erick Turcios, Csecsei, Gyongyi, Csiky, Botond, Danos, Peter, Deak, Laszlo, Dudas, Mihaly, Harcsa, Eleonora, Keltai, Katalin, Keresztesi, Sandor, Kiss, Krisztian, Konyves, Laszlo, Major, Lajos, Mileder, Margit, Molnar, Marta, Mucsi, Janos, Oroszlan, Tamas, Ory, Ivan, Paragh, Gyorgy, Peterfai, Eva, Petro, Gizella, Revesz, Katalin, Takacs, Robert, Vangel, Sandor, Vasas, Szilard, Zsom, Marianna, Abraham, Oomman, Bhushan, Raju Sree, Deepak, Dewan, Edwin, Fernando M., Gopalakrishnan, Natarajan, Gracious, Noble, Hansraj, Alva, Jain, Dinesh, Keshavamurthy, C.B., Khullar, Dinesh, Manisha, Sahay, Peringat, Jayameena, Prasad, Narayan, Satyanarayana, Rao K., Sreedhar, Reddy, Sreelatha, Melemadathil, Sudhakar, Bhimavarapu, Chandra Vyasam, Ramesh, Bonadonna, Riccardo, Castellino, Pietro, Ceriello, Antonio, Chiovato, Luca, De Cosmo, Salvatore, Derosa, Giuseppe, Di Carlo, Alberto, Di Cianni, Graziano, Frascà, Giovanni, Fuiano, Giorgio, Gambaro, Giovanni, Garibotto, Giacomo, Giorda, Carlo, Malberti, Fabio, Mandreoli, Marcora, Mannucci, Edoardo, Orsi, Emanuela, Piatti, Piermarco, Santoro, Domenico, Sasso, Ferdinando Carlo, Serviddio, Gaetano, Stella, Andrea, Trevisan, Roberto, Veronelli, Anna Maria, Zanoli, Luca, Akiyama, Hitoshi, Aoki, Hiromi, Asano, Akimichi, Iitsuka, Tadashi, Kajiyama, Shizuo, Kashine, Susumu, Kawada, Toshio, Kodera, Takamoto, Kono, Hiroshi, Koyama, Kazunori, Kumeda, Yasuro, Miyauchi, Shozo, Mizuyama, Kazuyuki, Niiya, Tetsuji, Oishi, Hiroko, Ota, Satoshi, Sakakibara, Terue, Takai, Masahiko, Tomonaga, Osamu, Tsujimoto, Mitsuru, Wakasugi, Masakiyo, Wakida, Yasushi, Watanabe, Takayuki, Yamada, Masayo, Yanagida, Kazuhiro, Yanase, Toshihiko, Yumita, Wataru, Gaupsiene, Egle, Kozloviene, Dalia, Navickas, Antanas, Urbanaviciene, Egle, Abdul Ghani, Rohana, Kadir, Khalid Abdul, Ali, Norsiah, Che Yusof, Mohd Daud, Gan, Chye Lee, Ismail, Mastura, Kong, Wei Yen, Lam, Swee Win, Lee, Li Yuan, Loh, Chek Loong, Manocha, Anita Bhajan, Ng, Kee Sing, Ahmad, Nik Nur Fatnoon Nik, Ratnasingam, Vanassa, Shudim, Saiful Shahrizal Bin, Vengadasalam, Paranthaman, Abraira Munoz, Luis David, Salazar, Melchor Alpizar, Cruz, Juan Baas, Soto, Mario Burgos, Ramos, Jose Chevaile, Wong, Alfredo Chew, Correa Rotter, Jose Ricardo, Escalante, Tonatiu Diaz, Enriquez Sosa, Favio Edmundo, Lozano, Fernando Flores, Flota Cervera, Luis Fernando, Baron, Paul Frenk, Ballesteros, Cecilia Garcia, Gomez Rangel, Jose David, Herrera Jimenez, Luis Enrique, Irizar Santana, Sergio Saul, Flores, Fernando Jimenez, Molina, Hugo Laviada, Luna Ceballos, Rosa Isela, del Campo Blanco, Belia Martin, Franco, Guadalupe Morales, Moreno Loza, Oscar Tarsicio, Rocha, Cynthia Mustieles, Vera, Gregorio Obrador, Castellanos, Ricardo Orozco, Calcaneo, Juan Peralta, Reyes Rosano, Miguel Angel, Pattzi, Hiromi Rodriguez, Guzman, Juan Rosas, Rucker Joerg, Isabel Erika, Saavedra Sanchez, Sandra Berenice, Sanchez Mijangos, Jose Hector, Sanson, Pablo Serrano, Tamayo y Orozco, Juan Alfredo, Chavez, Eloisa Tellez, Cepeda, Alejandro Valdes, Carrillo, Luis Venegas, Mesa, Juan Villagordoa, Escobedo, Rolando Zamarripa, Baker, John, Noonan, Paul, Scott, Russell, Walker, Robert, Watson, Edward, Williams, Michael, Young, Simon, Abejuela, Zaynab, Agra, Jeimeen, Aquitania, Grace, Caringal, Clodoaido, Comia, Rhea Severina, Santos, Lalaine Delos, Gomez, Olivert, Jimeno, Cecilia, Tan, Gerry, Tolentino, Marsha, Yao, Christy, Yap, Yvette Ethel, Lallaine Ygpuara, Ma. Dovie, Bijata-Bronisz, Renata, Hotlos, Lucyna, Januszewicz, Andrzej, Kaczmarek, Barbara, Kaminska, Anna, Lazuka, Lech, Madej, Andrzej, Mazur, Stanislaw, Mlodawska-Choluj, Dorota, Nowicki, Michal, Orlowska-Kowalik, Grazyna, Popenda, Grazyna, Rewerska, Barbara, Sowinski, Dariusz, Angelescu, Liliana Monica, Anghel, Veronica, Avram, Rodica-Ioana, Busegeanu, Mihaela-Magdalena, Cif, Adriana, Cosma, Dana, Crisan, Carmen, Demian, Luiza Despina, Ferariu, Ioana Emilia, Halmagyi, Ildiko, Hancu, Nicolae, Munteanu, Mircea, Negru, Doru, Onaca, Adriana Gabriela, Petrica, Ligia, Popa, Amorin Remus, Ranetti, Aurelian-Emil, Serafinceanu, Cristian, Toarba, Cristina, Agafyina, Alina, Barbarash, Olga, Barysheva, Olga, Chizhov, Daniil, Dobronravov, Vladimir, Glinkina, Irina, Grineva, Elena, Khirmanov, Vladimir, Kolmakova, Elena, Koroleva, Tatiana, Kvitkova, Liudmila, Marasaev, Viacheslav, Mkrtumyan, Ashot, Morugova, Tatiana, Nagibovich, Galina, Nagibovich, Oleg, Nedogoda, Sergei, Osipova, Irina, Raskina, Tatiana, Samoylova, Yulia, Sazonova, Olga, Shamkhalova, Minara, Shutemova, Elena, Shwartz, Yuriy, Uriasyev, Oleg, Vorobyev, Sergey, Zateyshchikova, Anna, Zateyshshikov, Dmitry, Zykova, Tatyana, Antic, Slobodan, Djordjevic, Miodrag, Kendereski, Aleksandra, Lalic, Katarina, Lalic, Nebojsa, Popovic-Radinovic, Vesna, Babikova, Jana, Benusova, Olga, Buganova, Ingrid, Culak, Jan, Dzupina, Andrej, Dzuponova, Jana, Fulop, Peter, Ilavska, Adriana, Martinka, Emil, Ochodnicka, Zuzana, Pella, Daniel, Smatanova, Iveta, Ahmed, Fayzal, Badat, Aysha, Breedt, Johannes, Distiller, Lawrence, Govender, Vimladhevi, Govender, Ravendran, Joshi, Mukesh, Jurgens, Jaco, Latiff, Gulam, Lombard, Landman, Mookadam, Mohamed, Ngcakani, Nomangesi, Nortje, Hendrik, Oosthuizen, Helena, Pillay-Ramaya, Larisha, Prozesky, Hans, Reddy, Jeevren, Rheeder, Paul, Seeber, Mary, Cho, Young Min, Jeong, In-Kyung, Kim, Sin Gon, Kim, Yeong Hoon, Kwon, Hyuk-Sang, Kwon, Min Jeong, Lee, Byung-Wan, Lee, JungEun, Lee, Moon-Kyu, Nam, Moon-Suk, Oh, Kook-Hwan, Park, Cheol- Young, Park, Sun-Hee, Yoon, Kun Ho, Garcia, Pere Alvarez, Mercadal, Luis Asmarats, Barrios, Clara, Castro, Fernando Cereto, Guldris, Secundino Cigarran, Lopez, Marta Dominguez, Egido de los Rios, Jesus, Fresnedo, Gema Fernandez, Serrano, Antonio Galan, Garcia, Isabel, Gonzalez Martinez, Francisco Javier, Jodar Gimeno, Jose Esteban, Mendoza, Manuel Lopez, Marin, Tamara Malek, Portillo, Cristobal Morales, Munar Vila, Maria Antonia, Torres, Manuel Muñoz, Iglesias, Javier Nieto, Perez, Jonay Pantoja, Vera, Merce Perez, Portoles Perez, Jose M., Quesada Simón, María Angustias, Canonge, Rafael Simo, Gonzalez, Alfonso Soto, Riera, Manel Terns, Tinahones Madueno, Francisco Jose, Plaza, Mercedes Velo, Chang, Chwen-Tzuei, Chuang, Lee-Ming, Hsia, Te-Lin, Hsieh, Chang-Hsun, Lin, Chih-Ching, Lu, Yung- Chuan, Sheu, Wayne H-H, Barna, Olga, Bilyk, Svitlana D., Botsyurko, Volodymyr, Dudar, Iryna, Fushtey, Ivan, Godlevska, Olga, Golovchenko, Oleksandr, Gyrina, Olga, Kazmirchuk, Anatoliy, Komisarenko, Iuliia, Korzh, Oleksii, Kravchun, Nonna, Legun, Oleg, Mankovskyy, Borys, Martynyuk, Liliya, Mostovoy, Yuriy, Pashkovska, Nataliia, Pererva, Larysa, Pertseva, Tetyana, Samoylov, Oleksandr, Smirnov, Ivan, Svyshchenko, Yevgeniya, Tomashkevych, Halyna, Topchii, Ivan, Tryshchuk, Nadiya, Tseluyko, Vira, Vizir, Vadym, Vlasenko, Maryna, Zlova, Tetiana, Zub, Liliia, Abusnana, Salah, Railey, Mohamed, Abouglila, Kamal, Ainsworth, Paul, Ali, Zishan, Arutchelvam, Vijayaraman, Barnard, Maria, Bellary, Srikanth, Davies, Emyr, Davies, Mark, Davies, Simon, Dawson, Alison, El Kossi, Mohsen, English, Patrick, Fraser, Donald, Gnudi, Luigi, Gunstone, Anthony, Hall, Timothy, Hanif, Wasim, Jackson, Alan, Johnson, Andrew, Joseph, Franklin, Krishnan, Singhan, Kumwenda, Mick, MacDougall, Iain, Nixon, Paul, O'Hare, Joseph, Philip, Sam, Ramtoola, Shenaz, Saxena, Manish, Sennik, Davesh, Simon, Godwin, Singh, Baldev, Stephens, Jeffrey, Strzelecka, Anna, Symonds, Rehan, Turner, Wayne, Wahba, Mona, Wakeling, John, Wheeler, David, Winocour, Peter, Abdallah, Joseph, Abdullah, Raied, Abramowitz, Matthew, Acosta, Idalia, Aiello, Joseph, Akright, Laura, Akyea-Djamson, Ayim, Alappan, Rajendran, Alicic, Radica, Al-Karadsheh, Amer, Allison, Dale Crawford, Arauz-Pacheco, Carlos, Arfeen, Shahabul, Arif, Ahmed, Arvind, Moogali, Atray, Naveen, Awad, Ahmed, Barnhill, Peggy, Barranco, Elizabeth, Barrera, Carlos, Beacom, Matthew, Behara, Venkata, Belo, Diogo, Bentley-Lewis, Rhonda, Berenguer, Ramon, Bermudez, Lidia, Bernardo, Marializa, Biscoveanu, Mihaela, Bowman-Stroud, Cynthia, Brandon, Donald, Brusco, Osvaldo, Busch, Robert, Canaan, Yamil, Chilito, Alicia, Christensen, Tom, Christiano, Cynthia, Christofides, Elena, Chuateco, Caroucel, Cohen, Kenneth, Cohen, Robert, Cohen-Stein, Debbie, Cook, Charles, Coyne, Daniel, Daboul, Nizar, Darwish, Riad, Daswani, Adarsh, Deck, Kenneth, Desouza, Cyrus, Dev, Devasmita, Dhillon, Monika, Dua, Sohan, Eder, Frank, Elosegui, Ana Maria, El-Shahawy, Mohamed, Ervin, John, Esquenazi, Alberto, Evans, John, Fishbane, Steven, Frias, Juan, Galindo-Ramos, Eugenia, Galphin, Claude, Ghazi, Adline, Gonzalez, Enrique, Gorson, David, Gowda, Anupama, Greco, Barbara, Grubb, Stephen, Gulati, Rakesh, Hammoud, Jamal, Handelsman, Stuart, Hartman, Israel, Hershon, Kenneth, Hiser, Daniel, Hon, George, Jacob, Radu, Jaime, Maria, Jamal, Aamir, Kaupke, Charles, Keightley, Gerald, Kern, Elizabeth, Khanna, Rakhi, Khitan, Zeid, Kim, Sun, Kopyt, Nelson, Kovesdy, Csaba, Krishna, Gopal, Kropp, Jeffrey (Jay), Kumar, Amrendra, Kumar, Jayant, Kumar, Neil, Kusnir, Jorge, Lane, Wendy, Lawrence, Mary, Lehrner, Lawrence, Lentz, John, Levinson, Dennis, Lewis, Derek, Liss, Kenneth, Maddux, Andreas, Maheshwari, Hiralal, Mandayam, Sreedhar, Marar, Isam, Mehta, Bhasker, Middleton, John, Mordujovich, Jorge, Moreda, Ramon, Moustafa, Moustafa, Trenche, Samuel Mujica, Narayanan, Mohanram, Narvarte, Javier, Nassar, Tareq, Newman, George, Nichol, Brian, Nicol, Philip, Nisnisan, Josier, Nossuli, A. Kaldun, Obialo, Chamberlain, Olelewe, Sarah, Oliver, Michael, O'Shaughnessy, Andrew, Padron, John, Pankhaniya, Rohit, Parker, Reginald, Patel, Devesh, Patel, Gnyandev, Patel, Nina, Pavon, Humberto, Perez, Armando, Perez, Carlos, Perlman, Alan, Pettis, Karlton, Pharr, Walter, Phillips, Andrea, Purighalla, Raman, Quesada-Suarez, Luis, Ranjan, Rajiv, Rastogi, Sanjeev, Reddy, Jakkidi, Rendell, Marc, Rich, Lisa, Robinson, Michael, Rodriguez, Hector, Rosas, Sylvia, Saba, Fadi, Sankaram, Rallabhandi, Sarin, Ravi, Schreiman, Robert, Scott, David, Sekkarie, Mohamed, Sensenbrenner, John, Shakeel, Muhammad, Shanik, Michael, Shaw, Sylvia, Smith, Stephen, Solomon, Richard, Sprague, Amy, Spry, Leslie, Suchinda, Pusadee, Sultan, Senan, Surampudi, Prasanth, Sussman, Sherry, Tan, Anjanette, Terrelonge, Antonio, Thompson, Michael, Trespalacios, Fernando, Trippe, Bruce, Trueba, Pilar, Twahirwa, Marcel, Updegrove, John, Van Buren, Peter, Vannorsdall, Mark, Varghese, Freemu, Velasquez-Mieyer, Pedro, Ventrapragada, Sailaja, Vukotic, Goga, Wadud, Khurram, Warren, Mark, Watson, Henry, Watts, Ronald, Weiner, Daniel, Welker, James, Welsh, Jean, Williams, Shelley, Zaniewski-Singh, Michelle, Yi, Tae Won, Smyth, Brendan, Di Tanna, Gian Luca, Arnott, Clare, Cardoza, Kathryn, and Kang, Amy

Published
2023
Full Text
View/download PDF

5. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

Author

Liao, Jinlan, Kang, Amy, Xia, Chao, Young, Tamara, Di Tanna, Gian Luca, Arnott, Clare, Pollock, Carol, Krishnan, Arun V., Agarwal, Rajiv, Bakris, George, Charytan, David M., de Zeeuw, Dick, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Mahaffey, Kenneth W., Perkovic, Vlado, Jardine, Meg J, and Smyth, Brendan

Published
2022
Full Text
View/download PDF

6. Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.

Author

Cardoza, Kathryn, Kang, Amy, Smyth, Brendan, Yi, Tae Won, Pollock, Carol, Agarwal, Rajiv, Bakris, George, Charytan, David M., de Zeeuw, Dick, Wheeler, David C., Zhang, Hong, Cannon, Christopher P., Perkovic, Vlado, Arnott, Clare, Levin, Adeera, and Mahaffey, Kenneth W.

Subjects
*TYPE 2 diabetes, *PROPORTIONAL hazards models, *DIABETIC nephropathies, *SODIUM-glucose cotransporter 2 inhibitors, CARDIOVASCULAR disease related mortality
Abstract

Aim: To explore the effect of canagliflozin on kidney and cardiovascular events and safety outcomes in individuals with type 2 diabetes and chronic kidney disease across geographic regions and racial groups. Materials and Methods: A stratified Cox proportional hazards model was used to assess efficacy and safety outcomes by geographic region and racial group. The primary composite outcome was a composite of end‐stage kidney disease (ESKD), doubling of the serum creatinine (SCr) level, or death from kidney or cardiovascular causes. Secondary outcomes included: (i) cardiovascular death or heart failure (HF) hospitalization; (ii) cardiovascular death, myocardial infarction (MI) or stroke; (iii) HF hospitalization; (iv) doubling of the SCr level, ESKD or kidney death; (v) cardiovascular death; (vi) all‐cause death; and (vii) cardiovascular death, MI, stroke, or hospitalization for HF or for unstable angina. Results: The 4401 patients were divided into six geographic region subgroups: North America (n = 1182, 27%), Central and South America (n = 941, 21%), Eastern Europe (n = 947, 21%), Western Europe (n = 421, 10%), Asia (n = 749, 17%) and Other (n = 161, 4%). The analyses included four racial groups: White (n = 2931, 67%), Black or African American (n = 224, 5%), Asian (n = 877, 20%) and Other (n = 369, 8%). Canagliflozin reduced the relative risk of the primary composite outcome in the overall trial by 30% (hazard ratio 0.70, 95% confidence interval 0.59‐0.82; P = 0.00001). Across geographic regions and racial groups, canagliflozin consistently reduced the primary composite endpoint without evidence of heterogeneity (interaction P values of 0.39 and 0.91, respectively) or significant safety outcome differences. Conclusions: Canagliflozin reduces the risk of kidney and cardiovascular events similarly across geographic regions and racial groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

Author

Young, Tamara K., Li, Jing-Wei, Kang, Amy, Heerspink, Hiddo J. L., Hockham, Carinna, Arnott, Clare, Neuen, Brendon L., Zoungas, Sophia, Mahaffey, Kenneth W., Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Neal, Bruce, and Jardine, Meg

Published
2021
Full Text
View/download PDF

8. 1818. A Network Meta-Analysis of Antibiotic Efficacy for the Treatment of Skin and Soft Tissue Infections

Author

Go-Wheeler, Marianne, primary, Mann, Sarah C, additional, Hean, Sindalisa, additional, Schwartz, Matthew H, additional, Pham, Ann, additional, Judge, Stephen, additional, Kang, Amy Y, additional, Lee, Pamela, additional, Gil, Raul Macias, additional, Launer, Bryn M, additional, Tao, Li, additional, Miller, Elliot I, additional, Flores, Evelyn A, additional, Nguyen, Megan H, additional, Yeh, Maddie, additional, Speciale, Christiana, additional, and Miller, Loren G, additional

Published
2023
Full Text
View/download PDF

10. 765. Development of an Adaptable Roadmap for Implementation of the Infectious Diseases Society of America Core Antimicrobial Stewardship Curriculum in Infectious Diseases Fellowship Programs

Author

Hojat, Leila S, primary, Patel, Payal K, additional, Nori, Priya, additional, Hamilton, Keith W, additional, Justo, Julie Ann, additional, Spicer, Jennifer O, additional, Logan, Ashleigh, additional, Bennani, Kenza, additional, Lee, Matthew S, additional, Bryson-Cahn, Chloe, additional, Stohs, Erica J, additional, Willis, Zachary, additional, Moenster, Ryan P, additional, Van Schooneveld, Trevor C, additional, Brennan-Krohn, Thea, additional, Beeler, Cole, additional, Kang, Amy Y, additional, Al Lawani, Hawra, additional, Cherabuddi, Kartik, additional, Fong, Gary, additional, Ince, Dilek, additional, Holubar, Marisa, additional, Paras, Molly L, additional, Gaston, David, additional, Shnekendorf, Rachel A, additional, Williams, Rostam, additional, and Luther, Vera, additional

Published
2023
Full Text
View/download PDF

12. A Three-Phased Fuzzy Logic Multi-Criteria Decision-Making Model for Evaluating Operation Systems for Smart TVs

Author

Kang, Amy H. I. Lee and He-Yau

Subjects
smart TV, operation system, artificial intelligence (AI), new product development (NPD), fuzzy TOPSIS
Abstract

Within the competitive global market and fast-advancing technology environment, in order to survive and to succeed, firms need to spontaneously respond to market changes and the uncertainty of customer needs. Therefore, New Product Development (NPD) is extremely important for the success of firms. Artificial Intelligence (AI) has gradually entered people’s lives, and consumer demand for AI products is increasing. Firms need to understand the AI development trend and consider the preferences of consumers for AI-related products under social changes so that suitable consumer AI products can be properly developed. In this study, the evaluation and selection of operation systems for a commercially available AI product (smart TV) is studied, and a Multi-Criteria Decision-Making (MCDM) model for facilitating the selection of the most suitable operation system for product development is constructed. The proposed model consists of three phases: Interpretative Structural Modelling (ISM) to construct a decision-making network, Fuzzy Analytic Network Process (FANP) to obtain the weights of factors, and Fuzzy Technique for Order of Preference by Similarity to Ideal Solution (fuzzy TOPSIS) to rank the operation systems. The proposed model is applied to select an operation system that companies can use to develop a smart TV. The results show that the proposed model can provide a systematic method that helps companies make appropriate operation system selection decisions.

Published
2023
Full Text
View/download PDF

14. Altered Tau Kinase Activity in rTg4510 Mice after a Single Interfaced CHIMERA Traumatic Brain Injury

Author

Cheng, Wai Hang, primary, Cheung, Honor, additional, Kang, Amy, additional, Fan, Jianjia, additional, Cooper, Jennifer, additional, Anwer, Mehwish, additional, Barron, Carlos, additional, Wilkinson, Anna, additional, Hu, Grace, additional, Yue, Jefferey, additional, Cripton, Peter A., additional, Vocadlo, David J., additional, and Wellington, Cheryl L., additional

Published
2023
Full Text
View/download PDF

15. The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

Author

Kang, Amy, primary, Smyth, Brendan, additional, Neuen, Brendon L., additional, Heerspink, Hiddo J. L., additional, Di Tanna, Gian Luca, additional, Zhang, Hong, additional, Arnott, Clare, additional, Hockham, Carinna, additional, Agarwal, Rajiv, additional, Bakris, George, additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Greene, Tom, additional, Levin, Adeera, additional, Pollock, Carol, additional, Wheeler, David C., additional, Mahaffey, Kenneth W., additional, Perkovic, Vlado, additional, and Jardine, Meg J., additional

Published
2023
Full Text
View/download PDF

16. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

Author

Yi, Tae Won, primary, Smyth, Brendan, additional, Di Tanna, Gian Luca, additional, Arnott, Clare, additional, Cardoza, Kathryn, additional, Kang, Amy, additional, Pollock, Carol, additional, Agarwal, Rajiv, additional, Bakris, George, additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Heerspink, Hiddo J.L., additional, Neal, Bruce, additional, Wheeler, David C., additional, Cannon, Christopher P., additional, Zhang, Hong, additional, Zinman, Bernard, additional, Perkovic, Vlado, additional, Levin, Adeera, additional, Mahaffey, Kenneth W., additional, and Jardine, Meg, additional

Published
2023
Full Text
View/download PDF

17. Altered tau in rTg4510 mice after a single interfaced CHIMERA traumatic brain injury

Author

Cheng, Wai Hang, primary, Cheung, Honor, additional, Kang, Amy, additional, Fan, Jianjia, additional, Cooper, Jennifer, additional, Anwer, Mehwish, additional, Barron, Carlos, additional, Wilkinson, Anna, additional, Hu, Grace, additional, Yue, Jefferey, additional, Cripton, Peter A, additional, Vocadlo, David, additional, and Wellington, Cheryl L, additional

Published
2022
Full Text
View/download PDF

19. Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

Author

Young, Tamara K., primary, Toussaint, Nigel D., additional, Di Tanna, Gian Luca, additional, Arnott, Clare, additional, Hockham, Carinna, additional, Kang, Amy, additional, Schutte, Aletta E., additional, Perkovic, Vlado, additional, Mahaffey, Kenneth W., additional, Agarwal, Rajiv, additional, Bakris, George L., additional, Charytan, David M., additional, Heerspink, Hiddo J. L., additional, Levin, Adeera, additional, Pollock, Carol, additional, Wheeler, David C., additional, Zhang, Hong, additional, and Jardine, Meg J., additional

Published
2022
Full Text
View/download PDF

23. Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure

Author

Kang, Amy, primary, Arnold, Ria, additional, Gallagher, Martin, additional, Snelling, Paul, additional, Green, Julianne, additional, Fernando, Mangalee, additional, Kiernan, Matthew C., additional, Hand, Samantha, additional, Grimley, Kim, additional, Burman, Jenny, additional, Heath, Anne, additional, Rogers, Kris, additional, Bhattacharya, Amritendu, additional, Smyth, Brendan, additional, Bradbury, Thomas, additional, Hawley, Carmel, additional, Perkovic, Vlado, additional, Krishnan, Arun V., additional, and Jardine, Meg J., additional

Published
2021
Full Text
View/download PDF

24. 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

Author

CARDOZA, KATHRYN, primary, KANG, AMY, additional, SMYTH, BRENDAN, additional, YI, TAE WON, additional, TANNA, GIAN LUCA DI, additional, POLLOCK, CAROL A., additional, DE ZEEUW, DICK, additional, WHEELER, DAVID C., additional, CANNON, CHRISTOPHER P., additional, ZINMAN, BERNARD, additional, JARDINE, MEG J., additional, ARNOTT, CLARE, additional, LEVIN, ADEERA, additional, and MAHAFFEY, KENNETH W., additional

Published
2021
Full Text
View/download PDF

25. 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Author

LIAO, JINLAN, primary, KANG, AMY, additional, XIA, CHAO, additional, ARNOTT, CLARE, additional, TANNA, GIAN LUCA DI, additional, KRISHNAN, ARUN V., additional, POLLOCK, CAROL A., additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, HEERSPINK, HIDDO L., additional, LEVIN, ADEERA, additional, DE ZEEUW, DICK, additional, NEAL, BRUCE, additional, ZHANG, HONG, additional, WHEELER, DAVID C., additional, ZINMAN, BERNARD, additional, MAHAFFEY, KENNETH W., additional, PERKOVIC, VLADO, additional, JARDINE, MEG J., additional, and SMYTH, BRENDAN, additional

Published
2021
Full Text
View/download PDF

26. Effect of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis

Author

Weiner, Maria, Goh, Su Mein, Mohammad, Aladdin J, Hrušková, Zdenka, Tanna, Anisha, Sharp, Phoebe, Kang, Amy, Bruchfeld, Annette, Selga, Daina, Chocová, Zdeňka, Westman, Kerstin, Eriksson, Per, Harper, Lorraine, Pusey, Charles D, Tesaŕ, Vladimír, Salama, Alan D, Segelmark, Mårten, Weiner, Maria, Goh, Su Mein, Mohammad, Aladdin J, Hrušková, Zdenka, Tanna, Anisha, Sharp, Phoebe, Kang, Amy, Bruchfeld, Annette, Selga, Daina, Chocová, Zdeňka, Westman, Kerstin, Eriksson, Per, Harper, Lorraine, Pusey, Charles D, Tesaŕ, Vladimír, Salama, Alan D, and Segelmark, Mårten

Abstract

OBJECTIVE: Age is a risk factor for organ damage, adverse events, and mortality in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). However, the relationship between treatment and damage, hospitalizations, and causes of death in elderly patients is largely unknown. METHODS: Consecutive patients from Sweden, England, and the Czech Republic diagnosed between 1997 and 2013 were included. Inclusion criteria were a diagnosis of MPA or GPA and age 75 years or more at diagnosis. Treatment with cyclophosphamide, rituximab, and corticosteroids the first three months was registered. Outcomes up to two years from diagnosis included vasculitis damage index (VDI), hospitalization, and cause of death. RESULTS: Treatment data was available for 167 of 202 patients. At two years, 4% had no items of damage. There was a positive association between VDI score at two years and Birmingham Vasculitis Activity Score at onset, and a negative association with treatment using cyclophosphamide or rituximab. Intravenous methylprednisolone dose was associated with treatment-related damage. During the first year, 69% of patients were readmitted to hospital. MPO-ANCA positivity and lower creatinine levels decreased the odds for readmission. The most common cause of death was infection, and this was associated with cumulative oral prednisolone dose. CONCLUSION: Immunosuppressive treatment with cyclophosphamide or rituximab in elderly patients with MPA and GPA was associated with development of less permanent organ damage and was not associated with hospitalization. However, higher doses of corticosteroids during the first three months was associated with treatment-related damage and fatal infections., Funding agencies: Ingrid Asp Foundation; Swedish Renal Foundation; National Institute for Health Research Imperial Biomedical Research Centre

Published
2020
Full Text
View/download PDF

28. Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data

Author

Zhang, Hongmei, primary, Rogers, Kris, additional, Sukkar, Louisa, additional, Jun, Min, additional, Kang, Amy, additional, Young, Tamara, additional, Campain, Anna, additional, Cass, Alan, additional, Chow, Clara K, additional, Comino, Elizabeth, additional, Foote, Celine, additional, Gallagher, Martin, additional, Knight, John, additional, Liu, Bette, additional, Lung, Thomas, additional, McNamara, Martin, additional, Peiris, David, additional, Pollock, Carol, additional, Sullivan, David, additional, Wong, Germaine, additional, Zoungas, Sophia, additional, Jardine, Meg, additional, and Hockham, Carinna, additional

Published
2020
Full Text
View/download PDF

29. Risk factors for incident kidney disease in older adults: an Australian prospective population‐based study.

Author

Kang, Amy, Sukkar, Louisa, Hockham, Carinna, Jun, Min, Young, Tamara, Scaria, Anish, Foote, Celine, Neuen, Brendon L., Cass, Alan, Pollock, Carol, Comino, Elizabeth, Lung, Thomas, Pecoits‐Filho, Roberto, Rogers, Kris, and Jardine, Meg J.

Subjects
*CHRONIC kidney failure, *SOCIAL determinants of health, *RISK assessment, *SOCIOECONOMIC factors, *QUESTIONNAIRES, *HEALTH behavior, *BODY mass index, *LONGITUDINAL method, *PROPORTIONAL hazards models, *POISSON distribution, *COMORBIDITY, *DISEASE risk factors, *ADULTS
Abstract

Background and Aim: To determine risk factors for incident chronic kidney disease (CKD) in a large population‐based cohort. Methods: This prospective opt‐in population‐based cohort study is based on the 45 and Up Study, where New South Wales residents aged ≥45 years were randomly sampled from the Services Australia database and agreed to complete the 45 and Up Study baseline questionnaire and have their responses linked to their health data in routinely collected databases. The primary outcome was the development of incident CKD, defined as eGFR < 60 mL/min/1.73 m2. CKD incidence was calculated using Poisson regression. Risk factors for incident CKD were assessed using Cox regression in multivariable models. Results: In 39 574 participants who did not have CKD at enrolment, independent factors associated with developing CKD included: older age, regional residence (HR 1.38 (1.27–1.50) for outer regional vs major city), smoking (1.13 (1.00–1.27) for current smoker vs non‐smoker), obesity (1.25 (1.16–1.35) for obese vs normal body mass index), diabetes mellitus (1.41 (1.33–1.50)), hypertension (1.53 (1.44–1.62)), coronary heart disease (1.13 (1.07–1.20)), depression/anxiety (1.16 (1.09–1.24)) and cancer (1.29 (1.20–1.39)). Migrants were less likely to develop CKD compared with people born in Australia (0.88 (0.83–0.94)). Gender, partner status and socioeconomic factors were not independently associated with developing CKD. Conclusions: This large population‐based study found multiple modifiable and non‐modifiable factors were independently associated with developing CKD. In the Australian setting, the risk of CKD was higher with regional residence. Differences according to socioeconomic status were predominantly explained by age, comorbidities and harmful health‐related behaviours. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Therapy escalation following an elevated HbA1c in adults aged 45 years and older living with diabetes in Australia: a real-world observational analysis

Author

Xie, Ying, primary, Baker, Jannah, primary, Young, Tamara, primary, Jun, Min, primary, Sukkar, Louisa, primary, Campain, Anna, primary, Kang, Amy, primary, Cass, Alan, primary, Hu, Ji, primary, Peiris, David, primary, Pollock, Carol, primary, Wong, Germaine, primary, Zoungas, Sophia, primary, Rogers, Kris, primary, Jardine, Meg, primary, and Hockham, Carinna, primary

Published
2020
Full Text
View/download PDF

31. P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

Author

Young, Tamara, primary, Li, Jing-wei, primary, Kang, Amy, primary, Heerspink, Hiddo, primary, Hockham, Carinna, primary, Arnott, Clare, primary, Neuen, Brendon, primary, Zoungas, Sophia, primary, Mahaffey, Kenneth W, primary, Perkovic, Vlado, primary, De Zeeuw, Dick, primary, Fulcher, Gregory, primary, Neal, Bruce, primary, and Jardine, Meg, primary

Published
2020
Full Text
View/download PDF

32. P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

Author

Kang, Amy, primary, Smyth, Brendan, primary, Neuen, Brendon, primary, Lambers Heerspink, Hiddo, primary, Di Tanna, Gian Luca, primary, Neal, Bruce, primary, Zhang, Hong, primary, Hockham, Carinna, primary, Agarwal, Rajiv, primary, Bakris, George, primary, Charytan, David M, primary, De Zeeuw, Dick, primary, Greene, Tom, primary, Levin, Adeera, primary, Pollock, Carol, primary, Wheeler, David, primary, Zinman, Bernard, primary, Mahaffey, Kenneth W, primary, Perkovic, Vlado, primary, and Jardine, Meg, primary

Published
2020
Full Text
View/download PDF

33. P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

Author

Kang, Amy, primary, Neuen, Brendon, primary, Lambers Heerspink, Hiddo, primary, Di Tanna, Gian Luca, primary, Neal, Bruce, primary, Zhang, Hong, primary, Hockham, Carinna, primary, Agarwal, Rajiv, primary, Bakris, George, primary, Charytan, David M, primary, De Zeeuw, Dick, primary, Greene, Tom, primary, Levin, Adeera, primary, Pollock, Carol, primary, Wheeler, David, primary, Zinman, Bernard, primary, Mahaffey, Kenneth W, primary, Perkovic, Vlado, primary, and Jardine, Meg, primary

Published
2020
Full Text
View/download PDF

34. Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study

Author

Sukkar, Louisa, primary, Kang, Amy, additional, Hockham, Carinna, additional, Young, Tamara, additional, Jun, Min, additional, Foote, Celine, additional, Pecoits-Filho, Roberto, additional, Neuen, Brendon, additional, Rogers, Kris, additional, Pollock, Carol, additional, Cass, Alan, additional, Sullivan, David, additional, Wong, Germaine, additional, Knight, John, additional, Peiris, David, additional, Gallagher, Martin, additional, and Jardine, Meg, additional

Published
2020
Full Text
View/download PDF

35. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Author

Arnott, Clare, primary, Li, Qiang, additional, Kang, Amy, additional, Neuen, Brendon L., additional, Bompoint, Severine, additional, Lam, Carolyn S. P., additional, Rodgers, Anthony, additional, Mahaffey, Kenneth W., additional, Cannon, Christopher P., additional, Perkovic, Vlado, additional, Jardine, Meg J., additional, and Neal, Bruce, additional

Published
2020
Full Text
View/download PDF

37. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.

Author

Young, Tamara K., Li, Jing-Wei, Kang, Amy, Heerspink, Hiddo J. L., Hockham, Carinna, Arnott, Clare, Neuen, Brendon L., Zoungas, Sophia, Mahaffey, Kenneth W., Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Neal, Bruce, and Jardine, Meg

Abstract

Aims/hypothesis: Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular and kidney outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program over a range of type 2 diabetes mellitus complexity, defined separately by baseline intensity of treatment, duration of diabetes and glycaemic control. Methods: We performed a post hoc analysis of the effects of canagliflozin on major adverse cardiovascular events (MACE) according to baseline glucose-lowering treatments (0 or 1, 2 or 3+ non-insulin glucose-lowering treatments, or insulin-based treatment), duration of diabetes (<10, 10 to 16, >16 years) and HbA1c (≤53.0 mmol/mol [<7.0%], >53.0 to 58.5 mmol/mol [>7.0% to 7.5%], >58.5 to 63.9 mmol/mol [>7.5 to 8.0%], >63.9 to 69.4 mmol/mol [8.0% to 8.5%], >69.4 to 74.9 mmol/mol [>8.5 to 9.0%] or >74.9 mmol/mol [>9.0%]). We analysed additional secondary endpoints for cardiovascular and kidney outcomes, including a combined kidney outcome of sustained 40% decline in eGFR, end-stage kidney disease or death due to kidney disease. We used Cox regression analyses and compared the constancy of HRs across subgroups by fitting an interaction term (p value for significance <0.05). Results: At study initiation, 5095 (50%) CANVAS Program participants were treated with insulin, 2100 (21%) had an HbA1c > 74.9 mmol/mol (9.0%) and the median duration of diabetes was 12.6 years (interquartile interval 8.0–18 years). Canagliflozin reduced MACE (HR 0.86 [95% CI 0.75, 0.97]) with no evidence that the benefit differed between subgroups defined by the number of glucose-lowering treatments, the duration of diabetes or baseline HbA1c (all p-heterogeneity >0.17). Canagliflozin reduced MACE in participants receiving insulin with no evidence that the benefit differed from other participants in the trial (HR 0.85 [95% CI 0.72, 1.00]). Similar results were observed for other cardiovascular outcomes and for the combined kidney outcome (HR for combined kidney outcome 0.60 [95% CI 0.47, 0.77]), with all p-heterogeneity >0.37. Conclusions/interpretation: In people with type 2 diabetes mellitus at high cardiovascular risk, there was no evidence that cardiovascular and renal protection with canagliflozin differed across subgroups defined by baseline treatment intensity, duration of diabetes or HbA1c. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study (Preprint)

Author

Foote, Celine, primary, Hockham, Carinna, additional, Sukkar, Louisa, additional, Campain, Anna, additional, Kang, Amy, additional, Young, Tamara, additional, Cass, Alan, additional, Chow, Clara K, additional, Comino, Elizabeth, additional, Gallagher, Martin, additional, Jan, Stephen, additional, Knight, John, additional, Liu, Bette, additional, McNamara, Martin, additional, Peiris, David, additional, Pollock, Carol, additional, Sullivan, David, additional, Wong, Germaine, additional, Zoungas, Sophia, additional, Rogers, Kris, additional, Jun, Min, additional, and Jardine, Meg, additional

Published
2019
Full Text
View/download PDF

40. Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis

Author

Weiner, Maria, primary, Goh, Su Mein, additional, Mohammad, Aladdin J., additional, Hrušková, Zdenka, additional, Tanna, Anisha, additional, Sharp, Phoebe, additional, Kang, Amy, additional, Bruchfeld, Annette, additional, Selga, Daina, additional, Chocová, Zdeňka, additional, Westman, Kerstin, additional, Eriksson, Per, additional, Harper, Lorraine, additional, Pusey, Charles D., additional, Tesař, Vladimír, additional, Salama, Alan D., additional, and Segelmark, Mårten, additional

Published
2019
Full Text
View/download PDF

41. Dr. Kang, et al, reply

Author

KANG, AMY, primary, ANTONELOU, MARILINA, additional, WONG, NIKKI L., additional, TANNA, ANISHA, additional, ARULKUMARAN, NISHKANTHA, additional, TAM, FREDERICK W.K., additional, and PUSEY, CHARLES D., additional

Published
2019
Full Text
View/download PDF

45. Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

Author

Smyth, Brendan, primary, Krishnan, Arun V, additional, Gallagher, Martin, additional, Kiernan, Matthew, additional, Snelling, Paul, additional, Hawley, Carmel, additional, Fernando, Mangalee, additional, Hand, Samantha, additional, Grimley, Kim, additional, Burman, Jenny, additional, Heath, Anne, additional, Kang, Amy, additional, Perkovic, Vlado, additional, and Jardine, Meg J, additional

Published
2019
Full Text
View/download PDF

46. IgG4-tubulointerstitial nephritis: a literature review following 5 cases in a single centre

Author

Rocha, Joana, Kang, Amy, Wong, Nikki, Westaby, Joseph, Roufosse, Candice, and Cook, Terence

Subjects
IgG4, fungi, tubulo-interstitial nephritis
Abstract

Immunoglobulin G4-related disease is a recently described systemic fibro-inflammatory disease, characterized by an infiltration of abundant IgG4+ plasma cells and lymphocytes, leading to tumour-like swellings of the involved organs, and variable degrees of fibrosis. Organ involvement can occur metachronously, and as IgG4 expressionin other tissues is less specific, renal biopsy often plays a critical role in diagnosis leading to prompt treatment, which can prevent renal damage and other organ failure. Tubulointerstitial nephritis is the most common renal feature. IgG4-renal involvement is challenging to diagnose and remains under-recognized, particularly in patients with single-organ involvement. The authors describe the only 5 cases of IgG4-RD with kidney involvement identified in the last 10 years in a tertiary referral nephrology centre that serves a population of 3 million people. These cases underline the importance of an early diagnosis of IgG4-related disease, since early treatment is usually effective. They also corroborate that clinical and histopathological features are heterogeneous and that complement may play a role in its pathogenesis

Published
2017

48. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients

Author

McAdoo, Stephen P., Tanna, Anisha, Hruskova, Zdenka, Holm, Lisa, Weiner, Maria, Arulkumaran, Nishkantha, Kang, Amy, Satrapova, Veronika, Levy, Jeremy, Ohlsson, Sophie, Tesar, Vladimir, Segelmark, Mårten, Pusey, Charles D., Imperial College Trust, Wellcome Trust, Imperial College Healthcare NHS Trust- BRC Funding, Vasculitis UK, and The Academy of Medical Sciences

Subjects
Science & Technology, Goodpasture syndrome, BASEMENT-MEMBRANE ANTIBODIES, MYELOPEROXIDASE, anti–neutrophil cytoplasm antibody, 1103 Clinical Sciences, Urology & Nephrology, urologic and male genital diseases, anti-GBM disease, anti-neutrophil cytoplasm antibody, glomerulonephritis, vasculitis, CLASSIFICATION, GOODPASTURES-DISEASE, Urologi och njurmedicin, ANTINEUTROPHIL CYTOPLASMIC ANTIBODY, Urology and Nephrology, AUTOANTIBODIES, CRESCENTIC GLOMERULONEPHRITIS, Life Sciences & Biomedicine, RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS, SPECIFICITY
Abstract

Co-presentation with both ANCA and anti-GBM antibodies is thought to be relatively rare. Current studies of such double-positive cases report small numbers and variable outcomes. To study this further we retrospectively analyzed clinical features and long-term outcomes of a large cohort of 568 contemporary patients with ANCA-associated vasculitis, 41 patients with anti-GBM disease, and 37 double-positive patients with ANCA and anti-GBM disease from four European centers. Double-positive patients shared characteristics of ANCA-associated vasculitis (AAV), such as older age distribution and longer symptom duration before diagnosis, and features of anti-GBM disease, such as severe renal disease and high frequency of lung hemorrhage at presentation. Despite having more evidence of chronic injury on renal biopsy compared to patients with anti-GBM disease, double-positive patients had a greater tendency to recover from being dialysis-dependent after treatment and had intermediate long-term renal survival compared to the single-positive patients. However, overall patient survival was similar in all three groups. Predictors of poor patient survival included advanced age, severe renal failure, and lung hemorrhage at presentation. No single-positive anti-GBM patients experienced disease relapse, whereas approximately half of surviving patients with AAV and double-positive patients had recurrent disease during a median follow-up of 4.8 years. Thus, double-positive patients have a truly hybrid disease phenotype, requiring aggressive early treatment for anti-GBM disease, and careful long-term follow-up and consideration for maintenance immunosuppression for AAV. Since double-positivity appears common, further work is required to define the underlying mechanisms of this association and define optimum treatment strategies. Funding Agencies|UK National Institute for Health Research (NIHR) Academic Clinical Lectureship; Wellcome Trust; NIHR Imperial Biomedical Research Centre; Charles University Hospital, Prague, Czech Republic [RVO-VFN64165]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results